Literature DB >> 6818147

Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay.

M Leinonen, C E Frasch.   

Abstract

An enzyme-linked immunosorbent assay was developed for measuring immunoglobulin class-specific antibodies to Neisseria meningitidis capsular polysaccharides. The polysaccharides were fixed to the solid phase by precoating the polystyrene surface with basic polyamino acids. Polylysine precoating was found to give optimal antibody values with the meningococcal polysaccharides studied. The enzyme-linked immunosorbent assay was used to measure antibodies against group B meningococcal polysaccharide in healthy adults and in patients with group B meningitis. Antibodies to group B polysaccharide in sera obtained from healthy adults were primarily immunoglobulin M (IgM). Although the antibody response to disease was mostly IgM, both IgG and IgM antibodies increased. Infection with group B organisms stimulated anti-group B polysaccharide antibodies even in young patients, aged 6 to 7 months, and the magnitude of the B polysaccharide response increased with the age of the patient.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818147      PMCID: PMC347876          DOI: 10.1128/iai.38.3.1203-1207.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Immunodiagnosis of infection with Schistosoma mansoni: enzyme-linked immunosorbent assay for detection of antibody to circulating antigen.

Authors:  G H Kelsoe; T H Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

2.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

3.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Serologic studies of meningococcal infection and polysaccharide vaccination.

Authors:  M S Artenstein; B L Brandt; E C Tramont; W C Branche; H D Fleet; R L Cohen
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

5.  ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes.

Authors:  B M Gray
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

6.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies.

Authors:  W D Zollinger; J W Boslego
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  22 in total

1.  Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Authors:  Samuel Moore; Esmé K Farley; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

2.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

3.  Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.

Authors:  S Harthug; E Rosenqvist; E A Høiby; T W Gedde-Dahl; L O Frøholm
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

4.  Immunoresponses to Neisseria meningitidis epitopes: primary versus secondary antiphosphorylcholine responses.

Authors:  J Faro; R Seoane; E Puentes; F Martínez Ubeira; B J Regueiro
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

5.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

Authors:  G Arakere; C E Frasch
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

Review 9.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

10.  Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

Authors:  S J Devi; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.